IntelGenx Technologies Corp.
IGX.TO
Toronto Stock Exchange0.24
CAD
+0.04
- -
IntelGenx Technologies Corp.
IGX.TO
(Toronto Stock Exchange)
Recent
price
0.24
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- IntelGenx Technologies Corp. IntelGenx Technologies Corp. (IGX.TO), now operating as Nualtis following a rebranding announced in June 2025, develops and manufactures pharmaceutical oral thin films utilizing proprietary platforms including VersaFilm for human health immediate- and controlled-release applications, VetaFilm for veterinary products, and AdVersa for mucoadhesive tablets; the company provides comprehensive services encompassing research and development partnerships, analytical method development and validation, clinical monitoring, intellectual property support, regulatory affairs assistance, technology transfer, GMP manufacturing scale-up from lab to commercial production, and stability testing. Headquartered in Saint-Laurent, Quebec, Canada, with founding roots in 2003, Nualtis serves pharmaceutical partners targeting unmet needs in areas such as migraine, pain management, nausea, opioid dependence, pediatric and geriatric populations, and animal health across geographic segments in Europe, Canada, and the United States, where Europe constitutes the majority of revenue. Recent major developments include its acquisition as a wholly owned subsidiary by atai Life Sciences AG, with court approval of the asset purchase in October 2024 and transaction closure by late September 2024; a third amended and restated loan agreement with atai in March 2024 providing up to US$2 million in convertible financing; operational restructuring, facility upgrades, and expanded alliances to support global growth; and the strategic rebranding to Nualtis in June 2025, signaling renewed focus on innovation, lifecycle management, accelerated timelines, and financial stability through its oral film technologies.